Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26141056 | 1.00 | HRH4 (0.42) | HRH4SMPD3HRH3ACACBEGLN2 | |
| SCHEMBL25098979 | 0.81 | HRH3 (0.41) | HRH4HRH3ACACBMAP4K4 | |
| SCHEMBL26141888 | 0.81 | HRH3 (0.41) | HRH4HRH3ACACBMAP4K4 | |
| SCHEMBL17148507 | 0.79 | ACACB (0.49) | HRH4SMPD3HRH3ACACBMAP4K4 | |
| SCHEMBL31015013 | 0.78 | KMT2A (0.53) | SMPD3 | |
| SCHEMBL31015395 | 0.78 | KMT2A (0.53) | SMPD3 | |
| SCHEMBL179375 | 0.77 | KDM4E (0.39) | HRH4 | |
| SCHEMBL26141050 | 0.77 | HTR2C (0.39) | HRH4HRH3 | |
| SCHEMBL26141054 | 0.76 | HRH3 (0.39) | HRH4HRH3 | |
| SCHEMBL12028962 | 0.76 | KDM4E (0.38) | HRH4SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | HRH4 166/4885SMPD3 1090/4885HRH3 756/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | HRH4 166/4885SMPD3 1090/4885HRH3 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.